Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

Semaglutide 2.4 mg has previously been approved for use in adults with a BMI above 30 kg/m2 and those with a BMI above 27 kg/m2 and a weight-related comorbidity, such as type 2 diabetes or hypertension.

Levels of the inflammatory marker C-reactive protein decrease in people with or without type 2 diabetes taking weekly semaglutide 2.4 mg, shows analysis of three STEP trials.

The substantial weight loss achieved with weekly semaglutide 2.4 mg is maintained if people continue to take the medication for 2 years, show the STEP 5 results.

Semaglutide at a dose of 2.4 mg/week results in substantial weight loss among adolescents with obesity, show the results of the STEP TEENS trial.

People who lose weight while taking semaglutide 2.4 mg regain two-thirds of what they lost during the first year after stopping the medication, shows the STEP 1 extension study.

Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.

medwireNews : Semaglutide will soon be available at a dose of 2.0 mg in the USA , following FDA approval.

Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.

The STEP 6 findings reveal significant weight loss, along with a reduction in abdominal visceral fat, in east Asian people with obesity taking a high dose of semaglutide.

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

Semaglutide will be available in concentrations of 0.25, 0.5, 1.0, 1.7, and 2.4 mg.

Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein, indicates further analysis of the PIONEER and SUSTAIN trials.

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

People with type 2 diabetes who lose weight while taking semaglutide have a parallel improvement in their health-related quality of life, particularly that related to physical exertion, report the STEP 2 investigators,

John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic.

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide.

medwireNews : The US FDA has approved the 2.4 mg weekly dose of semaglutide to treat obesity regardless of the presence of type 2 diabetes.

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.